Evidence map›Paper›PMID 41859070›Full record

ArticleInfection and drug resistance2026

Mutations in

Sen Yang, Chao Xia, Xiaoman Zheng, Yanqiu Lu, Jiaoyu Deng, Yaokai Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sen Yang *Clinical Research Center, Chongqing Public Health Medical Center, Chongqing, People's Republic of China.
Chao Xia *Clinical Research Center, Chongqing Public Health Medical Center, Chongqing, People's Republic of China.
Xiaoman ZhengClinical Research Center, Chongqing Public Health Medical Center, Chongqing, People's Republic of China.
Yanqiu LuClinical Research Center, Chongqing Public Health Medical Center, Chongqing, People's Republic of China.
Jiaoyu DengKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
Yaokai ChenClinical Research Center, Chongqing Public Health Medical Center, Chongqing, People's Republic of China.ORCID 0000-0002-3229-0108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: As a first line anti-tuberculosis drug, isoniazid (INH) has been extensively used for decades. Consequently, resistance of Methods: The presence of mutations in Results: None of the 73 INH-susceptible isolates (0%), 18 of 26 INH mono-resistant isolates (69.2%), 188 of 199 MDR (multidrug resistant) isolates (94.5%), and 176 of 192 pre-XDR/XDR (pre-extensively drug-resistant) isolates (91.7%) had mutations in Conclusion: Mutation in

Indexed as

isoniazidkatGMycobacterium tuberculosisoxyR-ahpCresistance

Identifiers

PMID41859070
PMCPMC12998331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.